Literature DB >> 10849190

Drug utilization pattern of antiepileptic drugs and traditional Chinese medicines in a general hospital in Taiwan - a pharmaco-epidemiologic study.

L C Chen1, Y F Chen, L L Yang, M H Chou, M F Lin.   

Abstract

OBJECTIVE: Studies on antiepileptic drug utilization are important for the optimization of drug therapy and drug control. The present study was to evaluate the drug utilization pattern of standard antiepileptic drugs and traditional Chinese medicines (TCMs) in the treatment of different types of epilepsy in a general hospital in Taiwan.
METHOD: The epileptic patients under antiepileptic drug treatment at Veterans General Hospital-Taipei were considered in the analysis. Current diagnosis was obtained by the neurologist in charge of the patient. All patients were interviewed by standard questionnaire designed to provide specific information on the types of antiepileptic drugs and details of their use. The questionnaire also sought to determine whether TCMs were used, and whether patients were using TCMs in combination with hospital standard treatment. The results were analysed by descriptive statistics.
RESULTS: 729 patients with epilepsy definitely diagnosed were analysed in the study. 445 patients (61.04%) were prescribed with one antiepileptic drug. Combinations of two antiepileptic drugs were prescribed to 261 patients (35.80%), and combinations of three or more antiepileptic drugs to 23 patients (3.16%). A total of 1039 antiepileptic drugs was prescribed, corresponding to an average 1.42 drugs per patient. The most frequently prescribed antiepileptic drug was carbamazepine (56.93%), followed by phenytoin (31.96%), valproate (30.73%) and clonazepam (14.13%). Among the 729 epileptic patients, 83.68% used standard antiepileptic drugs alone, 16.32% used antiepileptic drugs in combination with TCMs.
CONCLUSION: Monotherapy is the type of therapy most frequently used in all types of seizures. The selection of antiepileptic drugs is based on efficacy for specific seizure types and epileptic syndromes. The most frequently prescribed antiepileptic drug was carbamazepine, followed by phenytoin, valproate and clonazepam. As some of the patients used TCMs for treatment of epilepsy even when scientific medicine has been provided, further studies on the possible interactions between TCMs and antiepileptic drugs are in progress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10849190     DOI: 10.1046/j.1365-2710.2000.00271.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  6 in total

Review 1.  Use of complementary and alternative medicine in epilepsy.

Authors:  Valeria Ricotti; Norman Delanty
Journal:  Curr Neurol Neurosci Rep       Date:  2006-07       Impact factor: 5.081

Review 2.  Prescribing antiepileptics for the elderly: differences between guideline recommendations and clinical practice.

Authors:  Mary Jo V Pugh; Perry J Foreman; Dan R Berlowitz
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

3.  Evaluation of unlicensed and off-label antiepileptic drugs prescribed to children: Brazilian Regulatory Agency versus FDA.

Authors:  Anna Paula de Sá Borges; Marília Silveira de Almeida Campos; Leonardo Régis Leira Pereira
Journal:  Int J Clin Pharm       Date:  2013-02-21

Review 4.  Interaction of carbamazepine with herbs, dietary supplements, and food: a systematic review.

Authors:  Sophia Yui Kau Fong; Qiong Gao; Zhong Zuo
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-19       Impact factor: 2.629

5.  Sociodemographic, Rationale Drug Use of Antiepileptic Drugs among Pediatric Patients with Epilepsy: A Prospective Study at a Tertiary Care Hospital.

Authors:  S Dwajani; E Adarsh; K S Nirmala; H Sahajananda
Journal:  J Neurosci Rural Pract       Date:  2019-10-09

6.  Adverse Drug Reactions of Anti-Epileptic Drugs in Children with Epilepsy: A Cross-Sectional Study.

Authors:  Sundeep Kaushik; Deepti Chopra; Suvasini Sharma; Satinder Aneja
Journal:  Curr Drug Saf       Date:  2019
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.